Clinical ProgressInvestors in XOMA can look forward to clinical progress from several of the Company’s 10 products in Phase 3 trials, with data announcements expected from key trials.
Financial StrengthXOMA ended the year financially strong with $106.8 million in cash, balanced by growing revenues from royalties and milestones.
Portfolio ExpansionXOMA has expanded its commercial asset portfolio to six products recently, through acquisitions and internal growth, which is expected to boost revenues by over 20% annually.